פרוזאק במינון נמוך עוזר לזרימת הדם
היי אומרית וברוכה הבאה לפורום, תרופות מהמשפחה של SSRI עוזרות לשיפור בזרימת הדם בחלקי המוח השונים, ודבר זה עוזר לילד לתקשר עם איזורי המוח השונים ומשפר את התפקוד התקשורתי שלו והופך אותו "פחות אוטיסט". במינון נמוך של התרופה יש פחות תופעות לוואי ויש את היתרון התקשורתי. אחד הרופאים שמשלב תרופות כמו משפחת ה-SSRI הוא דר'
גולדברג במינון שהוא הרבה הרבה פחות מהמינון הרגיל לטיפול בדיכאון. יש לו נסיון עם אלפי ילדים אוטיסטים הנמצאים בטיפולו ובאתר שלו יש גם פורום מצויין שבו את יכולה לשאול הורים לגבי תופעות הלוואי. בארץ יש נטייה לתת את התרופה הזו רק אחרי גיל 6 משום מה. והנה קצת מידע ממאמרים: Fukuda T, Sugie H, Ito M, Sugie Y. Department of Pediatric Neurology, Hamamatsu City Medical Center for Developmental Medicine, Hamamatsu, Shizuoka. The serotonin system has been implicated in the pathoetiology of autistic disorder. To examine the clinical effects of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) in children with autistic disorder, eighteen patients underwent a cross-over, double-blind trial of fluvoxamine treatment after a written informed consent was obtained from patients' parents. Fluvoxamine treatment resulted in significant improvements in some clinical findings such as eye contact and language use, as tested by behavioral assessment scores consisting of twenty items (p < 0.05). The improvement in language use was also confirmed by parental assessments. Clinical Global Impression Scale was improved in approximately half of the patients. No severe adverse effect was observed during the trial. Thus SSRI treatment in autistic children may be of value. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. DeLong GR, Ritch CR, Burch S. Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
[email protected] One hundred and twenty-nine children, 2 to 8 years old, with idiopathic autistic spectrum disorder diagnosed by standard instruments (Childhood Austim Ratings Scale and Autism Diagnostic Observation Schedule) were treated with fluoxetine (0.15 to 0.5mg/kg) for 5 to 76 months (mean 32 to 36 months), with discontinuation trials. Response criteria are described. Family histories were obtained using the family history method in repeated interviews. Fluoxetine response, family history of major affective disorder, and unusual intellectual achievement, pretreatment language, and hyperlexia were used to define a coherent subgroup of autistic spectrum disorder. Statistical analyses were post hoc. Of the children, 22 (17%) had an excellent response, 67 (52%) good, and 40 (31%) fair/poor. Treatment age did not correlate with response. Fluoxetine response correlated robustly with familial major affective disorder and unusual intellectual achievement, and with hyperlexia in the child. Family history of bipolar disorder and of unusual intellectual achievement correlated strongly. Five children developed bipolar disorder during follow-up. Fluoxetine response, family history of major affective disorder (especially bipolar), unusual achievement, and hyperlexia in the children appear to define a homogeneous autistic subgroup. Bipolar disorder, unusual intellectual achievement, and autistic spectrum disorders cluster strongly in families and may share genetic determinants.
